Dyne Therapeutics, Inc.

DYN

US26818M1080

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2024 am IST			5-day change	1st Jan Change
41.48 ^USD	-6.05%		+4.88%	+211.88%

09/07	JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating	MT
01/07	Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Small Cap Comp Value Index	CI

Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Microcap Value Index

July 01, 2024

Latest news about Dyne Therapeutics, Inc.

JPMorgan Adjusts Price Target on Dyne Therapeutics to $43 From $39, Maintains Overweight Rating	09/07	MT
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Small Cap Comp Value Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000 Value Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Microcap Value Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Value Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Microcap Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 2500 Value Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 2000 Value Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell Microcap Growth Index	01/07	CI
Dyne Therapeutics, Inc.(NasdaqGS:DYN) dropped from Russell 3000E Growth Index	01/07	CI
Dyne Therapeutics Insider Sold Shares Worth $1,401,902, According to a Recent SEC Filing	25/06	MT
Dyne Therapeutics Insider Sold Shares Worth $1,334,201, According to a Recent SEC Filing	14/06	MT
Dyne Therapeutics, Inc. Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress	14/06	CI
Dyne Therapeutics Insider Sold Shares Worth $2,583,782, According to a Recent SEC Filing	12/06	MT
Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing	23/05	MT
Dyne Therapeutics Prices $325.5 Million Common Stock Offering	22/05	MT
Chardan Raises Price Target on Dyne Therapeutics to $42 From $31, Cites Additional Positive Data on DYNE-101, DYNE-251; Buy Rating Kept	21/05	MT
Dyne Therapeutics Launches $300 Million Share Offering	21/05	MT
Dyne Shares Rise After Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles	20/05	MT
HC Wainwright Adjusts Price Target on Dyne Therapeutics to $48 From $46, Maintains Buy Rating	20/05	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	20/05	MT
Transcript : Dyne Therapeutics, Inc. - Special Call	20/05
Dyne Says Trial Data of DYNE-101, DYNE-251 Showed Improvements in Functional Endpoints, Favorable Safety Profiles	20/05	MT
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints	20/05	CI

Dyne Therapeutics Inc. is a clinical-stage muscle disease company. It is focused on advancing life-transforming therapeutics for people living with genetically driven diseases. It is utilizing its FORCE platform to overcome the limitations of muscle tissue delivery and oligonucleotide therapeutics for muscle diseases. Its FORCE platform therapeutics consist of an oligonucleotide payload that is designed to target the genetic basis of the disease. Using its FORCE platform, it is assembling a portfolio of muscle disease therapeutics, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Its therapeutics consist of three components: a Fab, a clinically validated linker, and an oligonucleotide payload that it attaches to its Fab using the linker. It also plans to expand its portfolio through development efforts focused on rare skeletal muscle diseases, as well as cardiac and metabolic muscle diseases.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

44.15 USD

Average target price

46.3 USD

Spread / Average Target

+4.87%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DYNE THERAPEUTICS, INC.	+211.88%	437.81Cr
MODERNA, INC.	+24.74%	4.8TCr
IQVIA HOLDINGS INC.	-0.47%	4.24TCr
LONZA GROUP AG	+43.96%	4.15TCr
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	3.16TCr
ICON PUBLIC LIMITED COMPANY	+17.96%	2.86TCr
CELLTRION, INC.	-4.47%	2.8TCr
UNITED THERAPEUTICS CORPORATION	+50.73%	1.46TCr
MEDPACE HOLDINGS, INC.	+42.56%	1.41TCr
BIO-TECHNE CORPORATION	+1.46%	1.26TCr

Other Biotechnology & Medical Research